nctId,briefTitle,overallStatus,phase,studyType,leadSponsor,conditions,drug_raw,drug_normalized,intervention_type,arm_label,arm_type,role,is_candidate_drug,is_combo,outcome_label_mvp,outcome_confidence_mvp,has_resultsSection,primary_endpoint_met_final,outcome_label_final,confidence_final,evidence_source,primary_outcome_title,primary_outcome_timeframe,primary_outcome_pvalues,notes_ctgov,pubmed_pmids,notes_pubmed
NCT06431763,A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.,COMPLETED,PHASE4,INTERVENTIONAL,Novartis Pharmaceuticals,Hypercholesterolemia,Inclisiran sodium,inclisiran sodium,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06431763,A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.,COMPLETED,PHASE4,INTERVENTIONAL,Novartis Pharmaceuticals,Hypercholesterolemia,BPA,bpa,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05888103,Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.,COMPLETED,PHASE3,INTERVENTIONAL,Novartis Pharmaceuticals,Primary Hypercholesterolemia or Mixed Dyslipidemia,Inclisiran,inclisiran,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part,"Baseline, Day 150",p=0.0001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001,,
NCT05888103,Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.,COMPLETED,PHASE3,INTERVENTIONAL,Novartis Pharmaceuticals,Primary Hypercholesterolemia or Mixed Dyslipidemia,Matching Placebo for Inclisiran,matching placebo for inclisiran,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part,"Baseline, Day 150",p=0.0001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001,,
NCT01778569,"The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)",COMPLETED,,OBSERVATIONAL,"National Heart, Lung, and Blood Institute (NHLBI)",Metabolic Disease | Cardiovascular Disease | Inflammation | Psoriasis,"Michael N Sack, M.D.",michael n sack m.d.,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04316676,The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI,COMPLETED,,INTERVENTIONAL,Emory University,Coronary Artery Disease,Regadenoson,regadenoson,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,,,,,,,,,,
NCT02311335,Genes Involved in Lipid Disorders,COMPLETED,,OBSERVATIONAL,"National Heart, Lung, and Blood Institute (NHLBI)",Lipid Disorders,"Robert D Shamburek, M.D.",robert d shamburek m.d.,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06626659,Lipoprotein (a) and Vascular Regenerative Cell Content,COMPLETED,,OBSERVATIONAL,Canadian Medical and Surgical Knowledge Translation Research Group,Cardiovascular Diseases | Atherosclerosis Cardiovascular Disease | Ischemic Heart Disease | Dyslipidemia,"Subodh Verma, MD",subodh verma md,UNKNOWN,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06626659,Lipoprotein (a) and Vascular Regenerative Cell Content,COMPLETED,,OBSERVATIONAL,Canadian Medical and Surgical Knowledge Translation Research Group,Cardiovascular Diseases | Atherosclerosis Cardiovascular Disease | Ischemic Heart Disease | Dyslipidemia,"David A Hess, PhD",david a hess phd,UNKNOWN,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04053166,Individualized Physical Activity and Carotid Plaque Instability,COMPLETED,,INTERVENTIONAL,Hospices Civils de Lyon,Carotid Atherosclerosis,blood sampling,blood sampling,BIOLOGICAL,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04068909,ObseRvation After Acute Coronary Syndrome for deveLopment of trEatment Options,COMPLETED,,OBSERVATIONAL,Central State Medical Academy,Acute Coronary Syndrome,"Dmitry A Zateyshchikov, prof",dmitry a zateyshchikov prof,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04560998,A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes,COMPLETED,PHASE3,INTERVENTIONAL,Novo Nordisk A/S,"Diabetes Mellitus, Type 2 | Peripheral Arterial Disease",Semaglutide,semaglutide,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Change in Maximum Walking Distance on a Constant Load Treadmill Test,"Baseline (week 0), end of treatment (week 52)",p=0.0004,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0004,,
NCT04560998,A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes,COMPLETED,PHASE3,INTERVENTIONAL,Novo Nordisk A/S,"Diabetes Mellitus, Type 2 | Peripheral Arterial Disease",Placebo (semaglutide),placebo semaglutide,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Change in Maximum Walking Distance on a Constant Load Treadmill Test,"Baseline (week 0), end of treatment (week 52)",p=0.0004,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0004,,
NCT04471792,Creatine Use and Muscle Stretching in Peripheral Artery Disease,COMPLETED,PHASE2,INTERVENTIONAL,Florida State University,Peripheral Arterial Disease,Creatine monohydrate,creatine monohydrate,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,Walking Distance,Baseline and after 4 weeks of intervention,p=0.38,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.38,,
NCT02505399,TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement,COMPLETED,PHASE4,INTERVENTIONAL,"University Hospital, Toulouse",Atherosclerosis,ticagrelor,ticagrelor,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT02505399,TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement,COMPLETED,PHASE4,INTERVENTIONAL,"University Hospital, Toulouse",Atherosclerosis,clopidogrel,clopidogrel,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00001204,Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers,COMPLETED,,OBSERVATIONAL,"National Heart, Lung, and Blood Institute (NHLBI)",Homozygous Familial Hypercholesterolemic,"Robert D Shamburek, M.D.",robert d shamburek m.d.,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06675175,"A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.",COMPLETED,PHASE1,INTERVENTIONAL,AstraZeneca,Chronic Kidney Disease | Atherosclerotic Cardiovascular Disease,AZD4144,azd4144,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05988684,Effect of Metformin on Carotid Atherosclerosis for Non-diabetic Patients With PsA (CAMPA Study),COMPLETED,PHASE4,INTERVENTIONAL,Chinese University of Hong Kong,PsA (Psoriatic Arthritis),Metformin,metformin,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06508437,Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease,COMPLETED,PHASE4,INTERVENTIONAL,"University Hospital, Tours",Coronary Artery Disease | Inflammatory Response | Atherosclerosis,Influenza Vaccination,influenza vaccination,BIOLOGICAL,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05708547,Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.,COMPLETED,,OBSERVATIONAL,Centre Hospitalier Universitaire Dijon,Coronary Atherosclerosis,Blood samples,blood samples,BIOLOGICAL,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT02117453,"Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides",COMPLETED,PHASE3,INTERVENTIONAL,Assistance Publique - Hôpitaux de Paris,ANCA-associated Primary Necrotizing Vasculitides,Rosuvastatin,rosuvastatin,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT02110303,DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury,COMPLETED,"PHASE2,PHASE3",INTERVENTIONAL,University of Edinburgh,Coronary Artery Disease,Ticagrelor,ticagrelor,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04626973,Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial,COMPLETED,,INTERVENTIONAL,Yonsei University,Atherosclerotic Cardiovascular Disease,Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin),ezetimibe statin combination therarpy ezetimibe plus rosuvastatin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04626973,Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial,COMPLETED,,INTERVENTIONAL,Yonsei University,Atherosclerotic Cardiovascular Disease,Statin monotherapy (rosuvastatin or atorvastatin),statin monotherapy rosuvastatin or atorvastatin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04626973,Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial,COMPLETED,,INTERVENTIONAL,Yonsei University,Atherosclerotic Cardiovascular Disease,Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin),ezetimibe statin combination therarpy ezetimibe plus rosuvastatin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04626973,Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial,COMPLETED,,INTERVENTIONAL,Yonsei University,Atherosclerotic Cardiovascular Disease,Statin monotherapy (rosuvastatin or atorvastatin),statin monotherapy rosuvastatin or atorvastatin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT07203677,Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT),COMPLETED,,OBSERVATIONAL,Brigham and Women's Hospital,Type2 Diabetes Mellitus | Atherosclerotic Cardiovascular Disease,Initiation of tirzepatide,initiation of tirzepatide,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT07203677,Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT),COMPLETED,,OBSERVATIONAL,Brigham and Women's Hospital,Type2 Diabetes Mellitus | Atherosclerotic Cardiovascular Disease,Initiation of sitagliptin,initiation of sitagliptin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT01180361,Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance,COMPLETED,,OBSERVATIONAL,NYU Langone Health,Rheumatoid Arthritis,"Allison B Reiss, MD",allison b reiss md,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT01419080,Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT),COMPLETED,,OBSERVATIONAL,Saint Luke's Health System,Peripheral Arterial Disease | Quality of Life | Quality of Care,"Kim Smolderen, PhD",kim smolderen phd,UNKNOWN,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT01419080,Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT),COMPLETED,,OBSERVATIONAL,Saint Luke's Health System,Peripheral Arterial Disease | Quality of Life | Quality of Care,"John A Spertus, MD, MPH",john a spertus md mph,UNKNOWN,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT04873934,Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome,COMPLETED,PHASE3,INTERVENTIONAL,Novartis Pharmaceuticals,Acute Coronary Syndrome,Inclisiran,inclisiran,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percent Change From Baseline to Day 330 in LDL-C,Baseline and Day 330,p=0.001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.001,,
NCT06005597,Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies,COMPLETED,PHASE3,INTERVENTIONAL,NewAmsterdam Pharma,Dyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | ASCVD | High Cholesterol,Monotherapy obicetrapib,monotherapy obicetrapib,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C,84 Days,p=0.0001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001,,
NCT06005597,Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies,COMPLETED,PHASE3,INTERVENTIONAL,NewAmsterdam Pharma,Dyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | ASCVD | High Cholesterol,Monotherapy ezetimibe,monotherapy ezetimibe,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C,84 Days,p=0.0001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001,,
NCT06942923,"A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity",COMPLETED,PHASE1,INTERVENTIONAL,AstraZeneca,Healthy Participants,AZD4144,azd4144,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00696124,Safety Study of Gene Therapy in Treating Critical Leg Ischemia,COMPLETED,PHASE1,INTERVENTIONAL,"Helixmith Co., Ltd.",Critical Limb Ischemia,VM202 2 mg,vm202 2 mg,BIOLOGICAL,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT00696124,Safety Study of Gene Therapy in Treating Critical Leg Ischemia,COMPLETED,PHASE1,INTERVENTIONAL,"Helixmith Co., Ltd.",Critical Limb Ischemia,VM202 4 mg,vm202 4 mg,BIOLOGICAL,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT00696124,Safety Study of Gene Therapy in Treating Critical Leg Ischemia,COMPLETED,PHASE1,INTERVENTIONAL,"Helixmith Co., Ltd.",Critical Limb Ischemia,VM202 8 mg,vm202 8 mg,BIOLOGICAL,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT00696124,Safety Study of Gene Therapy in Treating Critical Leg Ischemia,COMPLETED,PHASE1,INTERVENTIONAL,"Helixmith Co., Ltd.",Critical Limb Ischemia,VM202 16 mg,vm202 16 mg,BIOLOGICAL,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT01064440,Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia,COMPLETED,PHASE2,INTERVENTIONAL,"Helixmith Co., Ltd.",Critical Limb Ischemia,Low Dose VM202,low dose vm202,BIOLOGICAL,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Number of Participants With Treatment-emergent Adverse Events Following Intramuscular Administration of 8 and 16 mg Engensis (VM202) or Placebo in Subjects With Critical Limb Ischemia.,"Baseline - Days 0, 14, 28, 42, 49, 90, 180, 270 and 365",,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,,PubMed search by NCTId; pmids=
NCT01064440,Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia,COMPLETED,PHASE2,INTERVENTIONAL,"Helixmith Co., Ltd.",Critical Limb Ischemia,High Dose VM202,high dose vm202,BIOLOGICAL,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Number of Participants With Treatment-emergent Adverse Events Following Intramuscular Administration of 8 and 16 mg Engensis (VM202) or Placebo in Subjects With Critical Limb Ischemia.,"Baseline - Days 0, 14, 28, 42, 49, 90, 180, 270 and 365",,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,,PubMed search by NCTId; pmids=
NCT07196280,Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies,COMPLETED,,OBSERVATIONAL,Chinese PLA General Hospital,Atherosclerotic Cardiovascular Disease (ASCVD) | Benign Prostatic Hypertrophy (BPH),5-Alpha Reductase Inhibitors,5-alpha reductase inhibitors,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT02685098,A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation,COMPLETED,PHASE1,INTERVENTIONAL,Indiana University,Ischemia | Peripheral Arterial Disease | Peripheral Vascular Disease | Vascular Disease | Arterial Occlusive Disease | Arteriosclerosis | Atherosclerosis | Cardiovascular Disease | Pathologic Processes | Orthopedic Procedures,Allogeneic bone marrow derived mesenchymal stem cells,allogeneic bone marrow derived mesenchymal stem cells,BIOLOGICAL,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05142722,Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies,COMPLETED,PHASE3,INTERVENTIONAL,NewAmsterdam Pharma,Dyslipidemias | High Cholesterol | Hypercholesterolemia | Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease,Obicetrapib,obicetrapib,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC],84 Days,p=0.0001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001,,
NCT03084523,Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRI,COMPLETED,PHASE1,INTERVENTIONAL,Yale University,Stroke | Intracranial Atherosclerosis,Ferumoxytol Injectable Product,ferumoxytol injectable product,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT07169682,Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis,COMPLETED,,OBSERVATIONAL,National and Kapodistrian University of Athens,Psoriasis | Cardiovascular Disease | Atherosclerosis,interleukin 17 inhibitor,interleukin 17 inhibitor,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT07169682,Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis,COMPLETED,,OBSERVATIONAL,National and Kapodistrian University of Athens,Psoriasis | Cardiovascular Disease | Atherosclerosis,interleukin-23 inhibitor,interleukin-23 inhibitor,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT07169682,Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis,COMPLETED,,OBSERVATIONAL,National and Kapodistrian University of Athens,Psoriasis | Cardiovascular Disease | Atherosclerosis,conventional systemic agent or apremilast,conventional systemic agent or apremilast,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT01447745,Abdominal Fat and Imaging Measurements of Heart Disease,COMPLETED,,OBSERVATIONAL,Laval University,Visceral Obesity | Atherosclerosis | Metabolic Syndrome,"DESPRÉS Jean-Pierre, PhD",després jean-pierre phd,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05761444,Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients,COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Atherosclerotic Cardiovascular Disease,Atozet 10/40 mg or 10/80 mg,atozet 10 40 mg or 10 80 mg,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 6,Baseline (Day 1) and Week 6,p=0.0001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001,,
NCT05761444,Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients,COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Atherosclerotic Cardiovascular Disease,Lipitor 40 mg or 80 mg,lipitor 40 mg or 80 mg,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 6,Baseline (Day 1) and Week 6,p=0.0001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001,,
NCT03900026,Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery,COMPLETED,PHASE4,INTERVENTIONAL,Unity Health Toronto,Coronary Artery Bypass Graft Surgery | Atherosclerosis | Vein Occlusion,Evolocumab,evolocumab,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05635370,Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol,COMPLETED,,OBSERVATIONAL,Brigham and Women's Hospital,Peripheral Artery Disease,Pentoxifylline,pentoxifylline,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT05635370,Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol,COMPLETED,,OBSERVATIONAL,Brigham and Women's Hospital,Peripheral Artery Disease,Cilostazol,cilostazol,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT06644651,Fat Around Heart Arteries as a Measure of Inflammation in Patients With Diabetes,COMPLETED,,OBSERVATIONAL,Odense University Hospital,"Atherosclerosis, Coronary | Diabetes Mellitus | Diabetes Mellitus Type 2 | Inflammation | Inflammation Plaque, Atherosclerotic | Perivascular Disease","Kenneth Egstrup, Professor",kenneth egstrup professor,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT02807779,Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging,COMPLETED,PHASE4,INTERVENTIONAL,"University of California, San Francisco",Peripheral Artery Disease | Vascular Disease | Critical Limb Ischemia,Dexamethasone infusion,dexamethasone infusion,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,Change in Percent Wall Volume (PWV),From Post-Operative Day One to 12 Months,p=0.22,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.22,,
NCT04382443,Oral Colchicine in Argentina to Prevent Restenosis,COMPLETED,PHASE4,INTERVENTIONAL,Centro de estudios en Cardiologia Intervencionista,Coronary Artery Disease | Restenosis of Coronary Artery Stent | Atherosclerosis | Acute Coronary Syndrome,Colchicine,colchicine,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05610280,"A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia",COMPLETED,PHASE3,INTERVENTIONAL,"Ionis Pharmaceuticals, Inc.",Hypertriglyceridemia | Cardiovascular Diseases | Atherosclerosis,Olezarsen,olezarsen,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04191746,BEST vCLI Registry,COMPLETED,,OBSERVATIONAL,Duke University,Critical Limb Ischemia,"Manesh Patel, MD",manesh patel md,UNKNOWN,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04191746,BEST vCLI Registry,COMPLETED,,OBSERVATIONAL,Duke University,Critical Limb Ischemia,"Sreekanth Vemulapalli, MD",sreekanth vemulapalli md,UNKNOWN,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05537571,Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events,COMPLETED,PHASE2,INTERVENTIONAL,Silence Therapeutics plc,Cardiovascular Diseases | Atherosclerosis | Lipoprotein(a),SLN360,sln360,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36,Week 36,"p=0.0001, p=0.0001, p=0.0001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001, p=0.0001, p=0.0001",,
NCT04061018,"The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux",COMPLETED,,OBSERVATIONAL,University of Texas Southwestern Medical Center,Lipid Metabolism Disorders,"Anand Rohatgi, MD",anand rohatgi md,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT07023445,Patterns of Inclisiran Use in the Real World: An Analysis of US Databases,COMPLETED,,OBSERVATIONAL,Novartis Pharmaceuticals,Atherosclerotic Cardiovascular Disease | Familial Hypercholesterolemia,Novartis Pharmaceuticals,novartis pharmaceuticals,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05192941,"Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia",COMPLETED,PHASE4,INTERVENTIONAL,Novartis Pharmaceuticals,Hypercholesterolemia,Inclisiran Sodium,inclisiran sodium,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06692764,A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure,COMPLETED,PHASE2,INTERVENTIONAL,AstraZeneca,Atherosclerotic Cardiovascular Disease,AZD0780,azd0780,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04992065,A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease,COMPLETED,PHASE2,INTERVENTIONAL,Novo Nordisk A/S,Atherosclerotic Cardiovascular Disease,NNC0385-0434 A 15 mg,nnc0385-0434 a 15 mg,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol,"Baseline (week 0), week 12","p=0.0001, p=0.0001, p=0.0001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001, p=0.0001, p=0.0001",,
NCT04992065,A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease,COMPLETED,PHASE2,INTERVENTIONAL,Novo Nordisk A/S,Atherosclerotic Cardiovascular Disease,NNC0385-0434 A 40 mg,nnc0385-0434 a 40 mg,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol,"Baseline (week 0), week 12","p=0.0001, p=0.0001, p=0.0001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001, p=0.0001, p=0.0001",,
NCT04992065,A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease,COMPLETED,PHASE2,INTERVENTIONAL,Novo Nordisk A/S,Atherosclerotic Cardiovascular Disease,NNC0385-0434 A 100 mg,nnc0385-0434 a 100 mg,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol,"Baseline (week 0), week 12","p=0.0001, p=0.0001, p=0.0001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001, p=0.0001, p=0.0001",,
NCT04992065,A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease,COMPLETED,PHASE2,INTERVENTIONAL,Novo Nordisk A/S,Atherosclerotic Cardiovascular Disease,"Evolocumab 140 mg/mL, Repatha®",evolocumab 140 mg ml repatha®,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol,"Baseline (week 0), week 12","p=0.0001, p=0.0001, p=0.0001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001, p=0.0001, p=0.0001",,
NCT03990545,Vessel Wall MR Imaging to Explore Sex-Differences of Intracranial Arterial Wall Changes After Suspected Stroke,COMPLETED,,OBSERVATIONAL,University of Pennsylvania,Intracranial Atherosclerosis | Acute Stroke | Transient Ischemic Attack,"Jae W Song, MD",jae w song md,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06659718,Emulation of the SOUL Diabetes Trial in Healthcare Claims,COMPLETED,,OBSERVATIONAL,Brigham and Women's Hospital,"Diabetes Mellitus, Type 2",Oral semaglutide,oral semaglutide,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06659718,Emulation of the SOUL Diabetes Trial in Healthcare Claims,COMPLETED,,OBSERVATIONAL,Brigham and Women's Hospital,"Diabetes Mellitus, Type 2",Sitagliptin,sitagliptin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06986369,Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases,COMPLETED,PHASE4,INTERVENTIONAL,The University of Hong Kong,"Atherosclerosis, Coronary",Rivaroxaban 2.5 MG Oral Tablet [Xarelto],rivaroxaban 2.5 mg oral tablet xarelto,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04929249,"A Randomized Study to Evaluate the Effect of an ""Inclisiran First"" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)",COMPLETED,PHASE3,INTERVENTIONAL,Novartis Pharmaceuticals,Atherosclerotic Cardiovascular Disease,Inclisiran,inclisiran,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percent Change From Baseline in LDL-C,"Baseline, Day 330",p=0.001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.001,,
NCT04270760,Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study,COMPLETED,PHASE2,INTERVENTIONAL,Amgen,Cardiovascular Disease,Olpasiran,olpasiran,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36,Baseline and Week 36,"p=0.001, p=0.001, p=0.001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.001, p=0.001, p=0.001",,
NCT05398029,A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease,COMPLETED,PHASE1,INTERVENTIONAL,"Verve Therapeutics, Inc.",Heterozygous Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | Hypercholesterolemia,VERVE-101,verve-101,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06048588,YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis,COMPLETED,"PHASE1,PHASE2",INTERVENTIONAL,"Beijing Inno Medicine Co., Ltd.",Atherosclerotic Cardiovascular Disease,YN001,yn001,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06048588,YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis,COMPLETED,"PHASE1,PHASE2",INTERVENTIONAL,"Beijing Inno Medicine Co., Ltd.",Atherosclerotic Cardiovascular Disease,Placebo for YN001,placebo for yn001,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06048588,YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis,COMPLETED,"PHASE1,PHASE2",INTERVENTIONAL,"Beijing Inno Medicine Co., Ltd.",Atherosclerotic Cardiovascular Disease,rosuvastatin calcium tablets,rosuvastatin calcium tablets,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04032197,A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes,COMPLETED,PHASE1,INTERVENTIONAL,Novo Nordisk A/S,"Diabetes Mellitus, Type 2",Semaglutide,semaglutide,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04032197,A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes,COMPLETED,PHASE1,INTERVENTIONAL,Novo Nordisk A/S,"Diabetes Mellitus, Type 2",Placebo (semaglutide),placebo semaglutide,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04377126,Unacylated Ghrelin to Improve Functioning in PAD,COMPLETED,PHASE2,INTERVENTIONAL,Northwestern University,Peripheral Artery Disease,Ghrelin,ghrelin,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06933745,Ultrasound Assessment of Atherosclerotic Plaque Burden and Cardiovascular Risk: A 10-Year Prospective Study,COMPLETED,,OBSERVATIONAL,"University Hospital, Akershus",Cardiovascular Diseases | Fatty Liver | Atherosclerosis of Femoral Artery | Carotid Artery Plaque | Stroke | Ischemic Cardiovascular Disease | Atheroscleroses,"Jonn-Terje Geitung, MD, PhD, MHA",jonn-terje geitung md phd mha,UNKNOWN,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06933745,Ultrasound Assessment of Atherosclerotic Plaque Burden and Cardiovascular Risk: A 10-Year Prospective Study,COMPLETED,,OBSERVATIONAL,"University Hospital, Akershus",Cardiovascular Diseases | Fatty Liver | Atherosclerosis of Femoral Artery | Carotid Artery Plaque | Stroke | Ischemic Cardiovascular Disease | Atheroscleroses,"Serena N.H. Tonstad, MD, PhD",serena n.h. tonstad md phd,UNKNOWN,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT02887859,Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD,COMPLETED,PHASE2,INTERVENTIONAL,"Humacyte, Inc.",Peripheral Artery Disease,Human Acellular Vessel (HAV),human acellular vessel hav,BIOLOGICAL,,,OTHER,1,0,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,"Number of Participants With Aneurysm Formation, Anastomotic Bleeding or Spontaneous Rupture, HAV Infection, HAV Removal, and Significant Inflammation at the HAV Implantation Site",12 months,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,,PubMed search by NCTId; pmids=
NCT02098460,To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject,COMPLETED,PHASE4,INTERVENTIONAL,Otsuka Beijing Research Institute,Severe Hypercholesterolemia,"Atorvastatin, Probucol, Cilostazol",atorvastatin probucol cilostazol,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00823849,Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker,COMPLETED,PHASE4,INTERVENTIONAL,Otsuka Beijing Research Institute,Type 2 Diabetes Mellitus | Arteriosclerosis Obliterans,Cilostazol,cilostazol,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00823849,Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker,COMPLETED,PHASE4,INTERVENTIONAL,Otsuka Beijing Research Institute,Type 2 Diabetes Mellitus | Arteriosclerosis Obliterans,Probucol,probucol,DRUG,3,EXPERIMENTAL,EXPERIMENTAL,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00823849,Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker,COMPLETED,PHASE4,INTERVENTIONAL,Otsuka Beijing Research Institute,Type 2 Diabetes Mellitus | Arteriosclerosis Obliterans,Cilostazol+Probucol,cilostazol+probucol,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05563246,A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events,COMPLETED,PHASE2,INTERVENTIONAL,Eli Lilly and Company,Lipoprotein Disorder,LY3473329,ly3473329,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay,"Baseline, Week 12","p=0.001, p=0.001, p=0.001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.001, p=0.001, p=0.001",,
NCT05129241,Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector,COMPLETED,,OBSERVATIONAL,Sanofi,Primary Hypercholesterolaemia and Mixed Dyslipidaemia | Atherosclerotic Cardiovascular Disease,Clinical Sciences & Operations,clinical sciences & operations,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04062734,Endovascular Treatment of Aorto-iliac Disease Using in Situ Fenestration,COMPLETED,,OBSERVATIONAL,Assistance Publique - Hôpitaux de Paris,Peripheral Artery Disease | Abdominal Aortic Aneurysm,"Raphaël COSCAS, MD, PhD",raphaël coscas md phd,UNKNOWN,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04062734,Endovascular Treatment of Aorto-iliac Disease Using in Situ Fenestration,COMPLETED,,OBSERVATIONAL,Assistance Publique - Hôpitaux de Paris,Peripheral Artery Disease | Abdominal Aortic Aneurysm,"Jérémie JAYET, MD",jérémie jayet md,UNKNOWN,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT03018366,"Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women",COMPLETED,PHASE2,INTERVENTIONAL,Cedars-Sinai Medical Center,Estrogen Deficiency | Cardiovascular Disease (CVD) | Functional Hypothalamic Amenorrhea | Endothelial Dysfunction,17beta Estradiol,17beta estradiol,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry,"Baseline, week 12 on trial",,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,37610989,PubMed search by NCTId; pmids=37610989
NCT03018366,"Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women",COMPLETED,PHASE2,INTERVENTIONAL,Cedars-Sinai Medical Center,Estrogen Deficiency | Cardiovascular Disease (CVD) | Functional Hypothalamic Amenorrhea | Endothelial Dysfunction,Transdermal placebo patch,transdermal placebo patch,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry,"Baseline, week 12 on trial",,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,37610989,PubMed search by NCTId; pmids=37610989
NCT03018366,"Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women",COMPLETED,PHASE2,INTERVENTIONAL,Cedars-Sinai Medical Center,Estrogen Deficiency | Cardiovascular Disease (CVD) | Functional Hypothalamic Amenorrhea | Endothelial Dysfunction,Progesterone,progesterone,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry,"Baseline, week 12 on trial",,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,37610989,PubMed search by NCTId; pmids=37610989
NCT03018366,"Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women",COMPLETED,PHASE2,INTERVENTIONAL,Cedars-Sinai Medical Center,Estrogen Deficiency | Cardiovascular Disease (CVD) | Functional Hypothalamic Amenorrhea | Endothelial Dysfunction,Placebo Pill,placebo pill,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry,"Baseline, week 12 on trial",,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,37610989,PubMed search by NCTId; pmids=37610989
NCT04881110,Liraglutide and Peripheral Artery Disease,COMPLETED,PHASE4,INTERVENTIONAL,University of Campania Luigi Vanvitelli,Type 2 Diabetes | Peripheral Arterial Disease,Liraglutide,liraglutide,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Peripheral Transcutaneous Oxygen Pressure,6 months,"p=0.001, p=0.001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.001, p=0.001",,
NCT04610892,Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction,COMPLETED,PHASE2,INTERVENTIONAL,AstraZeneca,Coronary Heart Disease (CHD),MEDI6570,medi6570,BIOLOGICAL,,,OTHER,1,0,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,"Change From Baseline to Day 253 in Non-calcified Plaque Volume in the Most Diseased Coronary Segment (NCPVMD), as Measured by Computed Tomography Angiography (CTA) Imaging",From baseline to Day 253,"p=0.065, p=0.563, p=0.685","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.065, p=0.563, p=0.685",,
NCT03981380,11C-PIB PET Study in MESA at Columbia University,COMPLETED,,OBSERVATIONAL,José A. Luchsinger,Cognitive Impairment | Vascular Diseases | Alzheimer Disease | Atherosclerosis,11C-PIB,11c-pib,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT03636152,Management of Cardiovascular Disease in Kidney Disease (MaCK) Study,COMPLETED,PHASE2,INTERVENTIONAL,VA Office of Research and Development,Chronic Kidney Disease | Cardiovascular Disease | Inflammation | Atherosclerosis | Aortic Stiffness,Hydroxychloroquine,hydroxychloroquine,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT03636152,Management of Cardiovascular Disease in Kidney Disease (MaCK) Study,COMPLETED,PHASE2,INTERVENTIONAL,VA Office of Research and Development,Chronic Kidney Disease | Cardiovascular Disease | Inflammation | Atherosclerosis | Aortic Stiffness,Matching Placebo,matching placebo,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04903756,The PERCEIVE Study,COMPLETED,,OBSERVATIONAL,Aneurin Bevan University Health Board,Amputation | Peripheral Artery Disease | Diabetes Mellitus,Health and Care Research Wales,health and care research wales,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05730621,A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease,COMPLETED,PHASE4,INTERVENTIONAL,Yuhan Corporation,Sarpogrelate | Blood Viscosity | Peripheral Arterial Disease | Coronary Artery Disease,Sarpogrelate Sustained Release/Aspirin,sarpogrelate sustained release aspirin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05730621,A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease,COMPLETED,PHASE4,INTERVENTIONAL,Yuhan Corporation,Sarpogrelate | Blood Viscosity | Peripheral Arterial Disease | Coronary Artery Disease,Aspirin,aspirin,DRUG,Sarpogrelate Sustained Release/Aspirin,EXPERIMENTAL,EXPERIMENTAL,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05159219,Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage,COMPLETED,PHASE2,INTERVENTIONAL,Population Health Research Institute,Intracranial Hemorrhages,Colchicine Pill,colchicine pill,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT03743636,Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease,COMPLETED,PHASE3,INTERVENTIONAL,Northwestern University,Peripheral Artery Disease,Nicotinamide riboside,nicotinamide riboside,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,Six-minute Walk Distance (NR Alone vs. Placebo),Baseline to 6-month follow-up,p=0.0775,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0775,,
NCT03743636,Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease,COMPLETED,PHASE3,INTERVENTIONAL,Northwestern University,Peripheral Artery Disease,Resveratrol,resveratrol,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,Six-minute Walk Distance (NR Alone vs. Placebo),Baseline to 6-month follow-up,p=0.0775,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0775,,
NCT03473223,Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome,COMPLETED,PHASE3,INTERVENTIONAL,CSL Behring,Acute Coronary Syndrome,Apolipoprotein A-I [human] (apoA-I),apolipoprotein a-i human apoa-i,BIOLOGICAL,,,OTHER,1,0,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,"Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke)",From the time of randomization through 90 days,p=0.121,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.121,,
NCT06020534,Aortoiliac Stenosis in Kidney Transplantation,COMPLETED,,OBSERVATIONAL,Erasmus Medical Center,Aorto-Iliac Arterial Stenosis | Peripheral Arterial Disease | Kidney Transplant Failure,"Yitian Fang, MD",yitian fang md,UNKNOWN,,,OTHER,1,0,UNCLEAR,LOW,1,,,,,,,,,,
NCT06753604,Gremlin-1 and Wagner Classification: Potential Biomarker for Amputation in Diabetic Foot Patients,COMPLETED,,OBSERVATIONAL,Seyma Acik,Diabetes Mellitus | Diabetic Foot Disease | Diabetic Foot Ulcer | Diabetic Neuropathy | Peripheral Arterial Disease,Ege University,ege university,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05797376,Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation,COMPLETED,PHASE4,INTERVENTIONAL,Asan Medical Center,Atherosclerosis of Artery | Coronary Artery Disease | Peripheral Arterial Disease | Carotid Stenosis,Rivaroxaban 2.5mg,rivaroxaban 2.5mg,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04167761,Ertugliflozin: Cardioprotective Effects on Epicardial Fat,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,Stanford University,Cardiovascular Diseases | Atherosclerosis | Type 2 Diabetes | Insulin Resistance,Ertugliflozin,ertugliflozin,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT02863926,Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA),COMPLETED,PHASE1,INTERVENTIONAL,Michael Murphy,Peripheral Artery Disease | Vascular Disease | Critical Limb Ischemia,Injection of cBMA aspirate into the index leg,injection of cbma aspirate into the index leg,BIOLOGICAL,,,OTHER,1,0,UNCLEAR,LOW,1,,,,,,,,,,
NCT06718465,Integrated Informatics-imaging Approaches to Cardiovascular Disease.,COMPLETED,,OBSERVATIONAL,University of Edinburgh,Atherosclerosis | Myocardial Infarction | Sudden Cardiac Death,Weill Medical College of Cornell University,weill medical college of cornell university,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05355402,"A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia",COMPLETED,PHASE2,INTERVENTIONAL,"Ionis Pharmaceuticals, Inc.",Hypertriglyceridemia | Atherosclerotic Cardiovascular Disease | Severe Hypertriglyceridemia,Olezarsen,olezarsen,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06702202,Effect of Subarachnoid Block and Femoropopliteal Block to Limb Perfusion in PAD Patients,COMPLETED,,INTERVENTIONAL,Indonesia University,Peripheral Arterial Disease | Subarachnoid Block | Femoropopliteal Block | Tissue Oxygen Saturation,Mixture of local anesthetics,mixture of local anesthetics,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06702202,Effect of Subarachnoid Block and Femoropopliteal Block to Limb Perfusion in PAD Patients,COMPLETED,,INTERVENTIONAL,Indonesia University,Peripheral Arterial Disease | Subarachnoid Block | Femoropopliteal Block | Tissue Oxygen Saturation,0.5% hyperbaric bupivacaine,0.5% hyperbaric bupivacaine,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06407154,"Chronical Illness-related Limitations of the Ability to Cope with Rising Temperatures: an Observational Study, 2nd Wave",COMPLETED,,OBSERVATIONAL,Universitätsklinikum Hamburg-Eppendorf,"Coronary Disease | Myocardial Infarction | Heart Failure | Arrhythmias, Cardiac | Peripheral Artery Disease | Stroke | Ischemic Attack, Transient | Diabetes Mellitus, Type 1 | Diabetes Mellitus, Type 2 | Pulmonary Disease, Chronic Obstructive","Ingmar Schäfer, PD Dr.",ingmar schäfer pd dr.,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT01872208,Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PAD,COMPLETED,,INTERVENTIONAL,"Humacyte, Inc.",Peripheral Arterial Disease | Peripheral Vascular Disease,HAV implantation,hav implantation,BIOLOGICAL,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05831319,"Evaluation of Standard of Care Practices, Procedural Outcomes and In-hospital Complications of Peripheral Endovascular Procedures",COMPLETED,,OBSERVATIONAL,Biotronik AG,Peripheral Arterial Disease,"Deloose Koen, Dr",deloose koen dr,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT03064126,RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty,COMPLETED,PHASE3,INTERVENTIONAL,Boston Scientific Corporation,"Peripheral Artery Disease | Atherosclerosis | Artery Diseases, Peripheral | Plaque, Atherosclerotic | Occlusive Arterial Disease",Paclitaxel,paclitaxel,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Number of Participants With Primary Lesion Patency,12 months (RCT); 6 months (LB substudy),p=0.0017,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0017,,
NCT05421078,A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.,COMPLETED,PHASE2,INTERVENTIONAL,NewAmsterdam Pharma,Dyslipidemia | Hypercholesterolemia | High Cholesterol,Obicetrapib,obicetrapib,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald],8 Weeks,"p=0.0001, p=0.0001, p=0.0001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001, p=0.0001, p=0.0001",,
NCT02376010,Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium,COMPLETED,PHASE4,INTERVENTIONAL,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,Atherosclerosis,rivaroxaban,rivaroxaban,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Coronary Artery Calcium (Serial Calcium Scans),1 year,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,,PubMed search by NCTId; pmids=
NCT02376010,Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium,COMPLETED,PHASE4,INTERVENTIONAL,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,Atherosclerosis,Warfarin,warfarin,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Coronary Artery Calcium (Serial Calcium Scans),1 year,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,,PubMed search by NCTId; pmids=
NCT06342609,Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease,COMPLETED,PHASE4,INTERVENTIONAL,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,Coronary Artery Disease,Colchicine 0.5 MG,colchicine 0.5 mg,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04807400,Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support,COMPLETED,PHASE3,INTERVENTIONAL,Novartis Pharmaceuticals,Atherosclerotic Cardiovascular Disease | Atherosclerotic Cardiovascular Disease Risk Equivelents | Elevated Low Density Lipoprotein Cholesterol,Inclisiran,inclisiran,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percentage Change in LDL-C From Baseline to Day 270,"Baseline, Day 270","p=0.001, p=0.001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.001, p=0.001",,
NCT04807400,Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support,COMPLETED,PHASE3,INTERVENTIONAL,Novartis Pharmaceuticals,Atherosclerotic Cardiovascular Disease | Atherosclerotic Cardiovascular Disease Risk Equivelents | Elevated Low Density Lipoprotein Cholesterol,Background lipid lowering therapy,background lipid lowering therapy,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Percentage Change in LDL-C From Baseline to Day 270,"Baseline, Day 270","p=0.001, p=0.001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.001, p=0.001",,
NCT02501018,Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI),COMPLETED,PHASE2,INTERVENTIONAL,"Lisata Therapeutics, Inc.",Critical Limb Ischemia | Buerger Disease | Thromboangiitis Obliterans | Atherosclerosis Obliterans,CLBS12,clbs12,BIOLOGICAL,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT02910271,Clinical Features and Prevalence of Asymptomatic Peripheral Artery Disease in Patients With Type 1 Diabetes Mellitus,COMPLETED,,OBSERVATIONAL,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,Type 1 Diabetes Mellitus | Peripheral Artery Disease,María Lía Nattero Chávez,maría lía nattero chávez,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT03006770,"Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization",COMPLETED,PHASE3,INTERVENTIONAL,Pluristem Ltd.,Critical Limb Ischemia (CLI),PLX-PAD,plx-pad,BIOLOGICAL,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04661644,Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia,COMPLETED,"PHASE1,PHASE2",INTERVENTIONAL,"S.Biomedics Co., Ltd.",Critical Limb Ischemia,Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial),clusters of adipose-derived mesenchymal stem cells dose 1 x 10^7 cells 1 ml vial,BIOLOGICAL,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04661644,Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia,COMPLETED,"PHASE1,PHASE2",INTERVENTIONAL,"S.Biomedics Co., Ltd.",Critical Limb Ischemia,Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial),clusters of adipose-derived mesenchymal stem cells dose 1 x 10^8 cells 1 ml vial,BIOLOGICAL,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT02106429,Platelet Activity in Vascular Surgery and Cardiovascular Events,COMPLETED,,OBSERVATIONAL,NYU Langone Health,Cardiovascular Disease | Peripheral Artery Disease | Critical Limb Ischemia,"Jeffrey Berger, MD",jeffrey berger md,UNKNOWN,,,OTHER,1,0,UNCLEAR,LOW,1,,,,,,,,,,
NCT01799811,Cryopreserved Saphenous Vein Allograft in Patients With Critical Limb Ischemia for Peripheral Revascularization,COMPLETED,,OBSERVATIONAL,"CryoLife, Inc.",Critical Limb Ischemia | Peripheral Arterial Disease,"Scott B Capps, MS",scott b capps ms,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT03253328,N-Acetyl-Cysteine (NAC) for Healing of Amputation Stumps in the Setting of Diabetes,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,Washington University School of Medicine,Diabetes Mellitus | Critical Limb Ischemia | Lower Limb Amputation Knee | Peripheral Arterial Disease,Active Arm N-acetyl cysteine (NAC),active arm n-acetyl cysteine nac,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT03253328,N-Acetyl-Cysteine (NAC) for Healing of Amputation Stumps in the Setting of Diabetes,COMPLETED,EARLY_PHASE1,INTERVENTIONAL,Washington University School of Medicine,Diabetes Mellitus | Critical Limb Ischemia | Lower Limb Amputation Knee | Peripheral Arterial Disease,Placebo Arm,placebo arm,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT00653835,Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Hypercholesterolaemia | Atherosclerosis,Ezetimibe + Simvastatin,ezetimibe + simvastatin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00653835,Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Hypercholesterolaemia | Atherosclerosis,Simvastatin,simvastatin,DRUG,Ezetimibe + Simvastatin,EXPERIMENTAL,EXPERIMENTAL,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00552097,Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578),COMPLETED,PHASE3,INTERVENTIONAL,Organon and Co,Atherosclerosis | Hypercholesterolemia | Hyperlipoproteinemia Type II,ezetimibe (plus simvastatin),ezetimibe plus simvastatin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00552097,Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578),COMPLETED,PHASE3,INTERVENTIONAL,Organon and Co,Atherosclerosis | Hypercholesterolemia | Hyperlipoproteinemia Type II,placebo (plus simvastatin),placebo plus simvastatin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00166530,EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Atherosclerosis,ezetimibe (+) simvastatin,ezetimibe + simvastatin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00166530,EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Atherosclerosis,simvastatin,simvastatin,DRUG,2,EXPERIMENTAL,EXPERIMENTAL,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00166530,EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Atherosclerosis,atorvastatin,atorvastatin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00650663,Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Hypercholesterolemia | Atherosclerosis,Ezetimibe + Simvastatin,ezetimibe + simvastatin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00650663,Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Hypercholesterolemia | Atherosclerosis,Simvastatin,simvastatin,DRUG,Ezetimibe + Simvastatin,EXPERIMENTAL,EXPERIMENTAL,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00653796,Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Hypercholesterolemia | Atherosclerosis,Ezetimibe + Atorvastatin,ezetimibe + atorvastatin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00653796,Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Hypercholesterolemia | Atherosclerosis,Atorvastatin,atorvastatin,DRUG,Ezetimibe + Atorvastatin,EXPERIMENTAL,EXPERIMENTAL,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT00651274,Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Atherosclerosis | Hypercholesterolemia | Coronary Heart Disease,Ezetimibe,ezetimibe,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04853719,Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients,COMPLETED,PHASE4,INTERVENTIONAL,Science Valley Research Institute,Peripheral Artery Disease | Intermittent Claudication,Rivaroxaban 2.5 Mg Oral Tablet,rivaroxaban 2.5 mg oral tablet,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05659888,Real Life Lipid Management in Hospitals Not Participating in PENELOPE Trial - Control Population for PENELOPE,COMPLETED,,OBSERVATIONAL,Clinical Operations WCN B.V.,Atherosclerotic Cardiovascular Disease | STEMI | Non STEMI,Marco Alings,marco alings,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT01397721,Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary,COMPLETED,,OBSERVATIONAL,Columbia University,Chronic Obstructive Pulmonary Disease,"R. Graham Barr, MD, DrPh",r. graham barr md drph,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06507852,"A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia",COMPLETED,,OBSERVATIONAL,Novartis,Atherosclerotic Cardiovascular Disease | Hypercholesterolemia,Novartis Pharmaceuticals,novartis pharmaceuticals,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04141579,Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody,COMPLETED,,INTERVENTIONAL,Radboud University Medical Center,Coronary Artery Disease | Atherosclerosis of Coronary Artery,Evolocumab 140 MG/ML [Repatha],evolocumab 140 mg ml repatha,DRUG,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT03689946,Effect of Evolocumab on Coronary Atherosclerosis,COMPLETED,PHASE3,INTERVENTIONAL,Cedars-Sinai Medical Center,Cardiovascular Disease | Hyperlipidemia,Evolocumab,evolocumab,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Change in Noncalcified Coronary Artery Plaque Volume (NCPV),baseline (pre-treatment) and 18 months after of treatment,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,"40178463,39343355","PubMed search by NCTId; pmids=40178463,39343355"
NCT03689946,Effect of Evolocumab on Coronary Atherosclerosis,COMPLETED,PHASE3,INTERVENTIONAL,Cedars-Sinai Medical Center,Cardiovascular Disease | Hyperlipidemia,Omnipaque,omnipaque,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Change in Noncalcified Coronary Artery Plaque Volume (NCPV),baseline (pre-treatment) and 18 months after of treatment,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,"40178463,39343355","PubMed search by NCTId; pmids=40178463,39343355"
NCT03689946,Effect of Evolocumab on Coronary Atherosclerosis,COMPLETED,PHASE3,INTERVENTIONAL,Cedars-Sinai Medical Center,Cardiovascular Disease | Hyperlipidemia,Metoprolol,metoprolol,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Change in Noncalcified Coronary Artery Plaque Volume (NCPV),baseline (pre-treatment) and 18 months after of treatment,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,"40178463,39343355","PubMed search by NCTId; pmids=40178463,39343355"
NCT03689946,Effect of Evolocumab on Coronary Atherosclerosis,COMPLETED,PHASE3,INTERVENTIONAL,Cedars-Sinai Medical Center,Cardiovascular Disease | Hyperlipidemia,Nitroglycerin,nitroglycerin,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Change in Noncalcified Coronary Artery Plaque Volume (NCPV),baseline (pre-treatment) and 18 months after of treatment,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,"40178463,39343355","PubMed search by NCTId; pmids=40178463,39343355"
NCT04753606,Randomized Study of Obicetrapib as an Adjunct to Statin Therapy,COMPLETED,PHASE2,INTERVENTIONAL,NewAmsterdam Pharma,Dyslipidemias | High Cholesterol | Hypercholesterolemia,Obicetrapib,obicetrapib,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald],8-weeks,"p=0.0001, p=0.0001","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001, p=0.0001",,
NCT05266586,Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy,COMPLETED,PHASE2,INTERVENTIONAL,NewAmsterdam Pharma,Dyslipidemias | High Cholesterol | Hypercholesterolemia,Obicetrapib,obicetrapib,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald],12-weeks,p=0.0001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001,,
NCT05266586,Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy,COMPLETED,PHASE2,INTERVENTIONAL,NewAmsterdam Pharma,Dyslipidemias | High Cholesterol | Hypercholesterolemia,Ezetimibe 10mg,ezetimibe 10mg,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald],12-weeks,p=0.0001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001,,
NCT05189847,Clinical Register Studying the therApeutic Patient Population With Multifocal Atherosclerosis,COMPLETED,,OBSERVATIONAL,Eurasian Association of Therapists,Polyvascular Disease | Atherosclerosis | Atherosclerosis Generalized | Cardiovascular Diseases | Cardiac Death | Chronic Kidney Diseases | Bleeding | Acute Stroke | Acute Coronary Syndrome,"Alexander Arutyunov, professor",alexander arutyunov professor,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT03363165,Hepatocyte Growth Factor to Improve Functioning in PAD,COMPLETED,PHASE2,INTERVENTIONAL,Northwestern University,Peripheral Artery Disease,VM202,vm202,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,Six-minute Walk Distance,Change from baseline to six-month follow-up in six-minute walk distance,p=0.7586,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.7586,,
NCT00496834,LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Hypertension,losartan potassium,losartan potassium,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug,Baseline and 24 Weeks,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,,PubMed search by NCTId; pmids=
NCT00496834,LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Hypertension,Comparator: carvedilol,comparator carvedilol,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug,Baseline and 24 Weeks,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,,PubMed search by NCTId; pmids=
NCT00496834,LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Hypertension,Comparator: losartan (+) hydrochlorothiazide (HCTZ),comparator losartan + hydrochlorothiazide hctz,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug,Baseline and 24 Weeks,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,,PubMed search by NCTId; pmids=
NCT00496834,LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED),COMPLETED,PHASE4,INTERVENTIONAL,Organon and Co,Hypertension,Comparator: carvedilol (+) hydrochlorothiazide,comparator carvedilol + hydrochlorothiazide,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug,Baseline and 24 Weeks,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,,PubMed search by NCTId; pmids=
NCT05742841,EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders),COMPLETED,PHASE4,INTERVENTIONAL,Wake Forest University Health Sciences,Lipid Disorder,moderate- or high-intensity statin/ rosuvastatin,moderate- or high-intensity statin rosuvastatin,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,U,UNCLEAR,LOW,UNRESOLVED,Low-density Lipoprotein Cholesterol (LDL-C) Levels at Baseline and Day 30,Baseline and Day 30,,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY).,,PubMed search by NCTId; pmids=
NCT05974345,In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease,COMPLETED,,OBSERVATIONAL,Novartis Pharmaceuticals,Atherosclerotic Cardiovascular Disease,Inclisiran sodium,inclisiran sodium,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05974345,In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease,COMPLETED,,OBSERVATIONAL,Novartis Pharmaceuticals,Atherosclerotic Cardiovascular Disease,Ezetimibe,ezetimibe,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05974345,In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease,COMPLETED,,OBSERVATIONAL,Novartis Pharmaceuticals,Atherosclerotic Cardiovascular Disease,Evolocumab,evolocumab,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04770389,Randomized Study of Obicetrapib in Combination With Ezetimibe,COMPLETED,PHASE2,INTERVENTIONAL,NewAmsterdam Pharma,Dyslipidemias | High Cholesterol | Hypercholesterolemia,Obicetrapib 5mg,obicetrapib 5mg,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald],8 weeks,p=0.0001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001,,
NCT04770389,Randomized Study of Obicetrapib in Combination With Ezetimibe,COMPLETED,PHASE2,INTERVENTIONAL,NewAmsterdam Pharma,Dyslipidemias | High Cholesterol | Hypercholesterolemia,Ezetimibe 10mg,ezetimibe 10mg,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,Y,POSITIVE,MED,CTGOV_STRUCTURED,Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald],8 weeks,p=0.0001,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0001,,
NCT05619042,Detection of Coronary Artery Calcifications by Whole Blood Transcriptome Analyzed by Artificial InTelligence Algorithms,COMPLETED,,OBSERVATIONAL,Santiago Gabriel Miriuka,"Atherosclerosis | Atheroscleroses, Coronary | Atherosclerotic Plaque","Santiago G Miriuka, MD MSc PhD",santiago g miriuka md msc phd,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT05733325,Diet-induced Elevations in LDL-C and Progression of Atherosclerosis,COMPLETED,,OBSERVATIONAL,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,Hypercholesterolemia,"Matthew A Budoff, MD",matthew a budoff md,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT04103034,"A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers",COMPLETED,PHASE1,INTERVENTIONAL,Band Therapeutics,Cerebrovascular Stroke | Large-Artery Atherosclerosis (Embolus/Thrombosis) | Intracranial Arteriosclerosis,BT200,bt200,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT04103034,"A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers",COMPLETED,PHASE1,INTERVENTIONAL,Band Therapeutics,Cerebrovascular Stroke | Large-Artery Atherosclerosis (Embolus/Thrombosis) | Intracranial Arteriosclerosis,Desmopressin,desmopressin,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,,,,,,,,,,
NCT05752968,Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease,COMPLETED,,OBSERVATIONAL,Tungs' Taichung Metroharbour Hospital,Endotoxemia | Peripheral Arterial Disease,"Paik Seong Lim, PhD",paik seong lim phd,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06167265,BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers,COMPLETED,PHASE1,INTERVENTIONAL,"Genovate Biotechnology Co., Ltd.,",Intermittent Claudication,Cilostazol Tablet 100 mg,cilostazol tablet 100 mg,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06167265,BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers,COMPLETED,PHASE1,INTERVENTIONAL,"Genovate Biotechnology Co., Ltd.,",Intermittent Claudication,PMR Tablet 145 mg,pmr tablet 145 mg,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT06187532,Carotid Plaque-Burden Scale and Outcomes. A Real Life Study,COMPLETED,,OBSERVATIONAL,Fundación para la Formación e Investigación de los Profesionales de la Salud de Extremadura,"Atheroscleroses, Cerebral | Carotid Plaque","JUAN SANCHEZ M-TORRERO, PhD",juan sanchez m-torrero phd,UNKNOWN,,,OTHER,1,0,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT02931188,The Effect of Anacetrapib on Vascular Function and Arterial Stiffness,COMPLETED,,OBSERVATIONAL,Cambridge University Hospitals NHS Foundation Trust,Atherosclerotic Cardiovascular Disease | Vascular Disease,Anacetrapib,anacetrapib,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
NCT02931188,The Effect of Anacetrapib on Vascular Function and Arterial Stiffness,COMPLETED,,OBSERVATIONAL,Cambridge University Hospitals NHS Foundation Trust,Atherosclerotic Cardiovascular Disease | Vascular Disease,Statin,statin,DRUG,,,OTHER,1,1,NO_RESULTS,HIGH,0,,,,,,,,,,
